Teva tots up $34B in financing for Allergan deal; Hetero rolls out Rituxan biosim in India;

@FiercePharma: ICYMI: Suit says CVS manipulated generic drug prices. Item | Follow @FiercePharma

@EricPFierce: As #Hospira expands recall of #ketorolac to 37M vials you've got to wonder what Pfizer thinks. Article | Follow @EricPFierce

@CarlyHFierce: #ICYMI Friday: Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO says. More | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) lined up more than $30 billion in financing for its $40 billion buyout of Allergan's ($AGN) generics business, with 11 lenders committing to the deal. Report

> Hetero Pharma rolled out its biosimilar version of Roche's ($RHHBY) Rituxan in India, under the brand name Maball; it will compete with versions from Dr. Reddy's Laboratories and Intas. Release

> Gilead Sciences' ($GILD) hepatitis C sales growth may be slowing, but with more than 2 million patients still untreated in the U.S., it's not going to run out of new business anytime soon. Report

> European regulators recommended Novartis' ($NVS) Revolade to treat severe aplastic anemia who haven't responded to immunosuppressive therapy. Report

> Citing the risk of hacking, the FDA recommended that hospitals stop using Hospira's ($HSP) Symbiq medication infusion pump. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Article | Follow @FierceMedDev

@VarunSaxena2: ResMed acquires China's Curative Medical to get bigger in sleep disorder devices. Item | Follow @VarunSaxena2

@EmilyWFierce: $OSUR got an FDA OK for emergency use of its rapid Ebola test. Press release | Follow @EmilyWFierce

> U.S. Army scientists roll out innovative blood loss monitor device. More

> Bard gets additional CMS reimbursement for its drug-coated angioplasty balloon. Story

Biotech News

@FierceBiotech: ICYMI Friday: Merck's Ebola vaccine is 100% successful in interim Phase III results. Report | Follow @FierceBiotech

@JohnCFierce: Is it just me, or is $SHPG's Ornskov overrated? Shire chief Ornskov bets $300M on another eye drug bolt-on buyout. Story | Follow @JohnCFierce

@DamianFierce: Charming addition to the drug co. nonsense lexicon: "biobetter." More | Follow @DamianFierce

> Sorrento buys into biosimilars with a Chinese antibody deal. Report

> Lexicon rockets up after a positive PhIII study sets up an NDA. Story

> AstraZeneca deepens its Isis ties with a $65M R&D pact. Article

Animal Health News

> VCA ups 2015 guidance as Q2 sales and profits soar past expectations. More

> Heska doubles Q2 operating income but misses on revenue. Report

> Schein misses Q2 estimates on currency woes and sales challenges. Story

> IDEXX shares climb on record diagnostics placements and Q2 earnings gain. Article

> Report: 'Precision farming' set to revolutionize livestock care. More

Biotech IT News

> Y Combinator continues push into bioinformatics with investment in Cofactor Genomics. News

> NIH to bankroll initiatives to build Cancer Genomics Cloud Pilots into R&D programs. Report

> Ex-BGI CEO's next move? A $1.6B push to find a 'formula for life.' More

> First startups graduate from Illumina Accelerator as deadline for next phase nears. Story

> Venter's HLI plans to ramp up sequencing capacity as more pharma deals near fruition. Article

Pharma Marketing News

> Express Scripts kicks another batch of meds off its preferred formulary. Item

> Pfizer's hot-selling Ibrance gets even hotter with new $710M sales estimate for 2015. News

> Sanofi and MannKind launch Afrezza DTC ad campaign in stealth mode. Story

> Shyft Analytics: Targeted drugs need a data-fueled marketing shift. Article

> Can a dwindling rep tally keep Vivus' obesity med in the game? More

And Finally ... The value of the Type 2 diabetes market is expected to hit $39 billion by 2021. Report